Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 601 to 650 of 1898

TitleReference numberPublishedLast updated
Heavy menstrual bleeding: assessment and managementNG88
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiographyMTG32
Parafricta Bootees and Undergarments to reduce skin breakdown in people with or at risk of pressure ulcersMTG20
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Permanent His-bundle pacemaker implantation for treating heart failureIPG694
UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasiaMTG58
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Repetitive short-pulse transscleral cyclophotocoagulation for glaucomaIPG692
Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adultsIPG693
Avelumab for treating metastatic Merkel cell carcinomaTA517
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liverIPG691
Postnatal careNG194
Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary painNG193
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Transcervical ultrasound-guided radiofrequency ablation for symptomatic uterine fibroidsIPG689
Extracorporeal whole liver perfusion for acute liver failureIPG690
Danis stent for acute oesophageal variceal bleedingMTG57
Cannabis-based medicinal productsNG144
Asthma: diagnosis, monitoring and chronic asthma managementNG80
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
QAngio XA 3D QFR and CAAS vFFR imaging software for assessing coronary stenosis during invasive coronary angiographyDG43
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Alpha-Stim AID for anxiety disordersMTG56
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681
Free-functioning gracilis transfer to restore upper limb function in brachial plexus injuryIPG687
Cytoreduction surgery with hyperthermic intraoperative peritoneal chemotherapy for peritoneal carcinomatosisIPG688
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribingNG190
Safeguarding adults in care homesNG189
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaTA677
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA678
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Metreleptin for treating lipodystrophyHST14
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675
Trabectedin for the treatment of advanced soft tissue sarcomaTA185
Mepolizumab for treating severe eosinophilic asthmaTA671
Brolucizumab for treating wet age-related macular degenerationTA672

Results per page

  1. 10
  2. 25
  3. 50
  4. All